Literature DB >> 30700447

Body Mass Index and Risk of Intestinal Metaplasia: A Cohort Study.

Kyungeun Kim1, Yoosoo Chang2,3,4, Jiin Ahn3, Hyo-Joon Yang5, Ju Young Jung6, Seokkyun Kim6, Chong Il Sohn5,6, Seungho Ryu2,3,4.   

Abstract

BACKGROUND: We examined the association between body mass index (BMI) and development of endoscopic intestinal metaplasia.
METHODS: This retrospective cohort study included 142,832 Korean adults free of endoscopic intestinal metaplasia and atrophic gastritis who underwent upper endoscopy at baseline and subsequent visits and were followed for up to 5 years. A parametric proportional hazards model was used to estimate the adjusted HR with 95% confidence interval (CI) for incident intestinal metaplasia.
RESULTS: In more than 444,719.1 person-years of follow-up, 2,281 participants developed endoscopic intestinal metaplasia (incidence rate, 5.1 per 1,000 person-years). Increased BMI categories were associated with increased risk of new-onset intestinal metaplasia in a dose-response manner. After adjustment for age, sex, center, year of screening exam, smoking status, alcohol intake, exercise, total calorie intake, history of diabetes and hypertension, and history of Helicobacter pylori infection, the multivariable adjusted HRs (95% CIs) for incident intestinal metaplasia comparing BMIs of <18.5, 23-24.9, 25.0-29.9, and >30 kg/m2 with a BMI of 18.5-22.9 kg/m2 were 0.84 (0.64-1.09), 1.03 (0.93-1.16), 1.07 (0.96-1.20), and 1.48 (1.20-1.83), respectively. These associations did not differ by clinically relevant subgroups. Risk of endoscopic atrophic gastritis also increased as the baseline BMI category increased.
CONCLUSIONS: In a large cohort of Korean men and women, obesity was independently associated with increased incidence of endoscopic atrophic gastritis and intestinal metaplasia. IMPACT: Excessive adiposity appears to play a role in development of stomach precursor lesions of stomach cancer, requiring further studies to determine whether strategies to reduce obesity will also help reduce precancerous lesions and, in turn, gastric cancer. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2019        PMID: 30700447     DOI: 10.1158/1055-9965.EPI-18-0733

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  3 in total

1.  Diabetes mellitus is associated with an increased risk of gastric cancer: a cohort study.

Authors:  Hyo-Joon Yang; Danbee Kang; Yoosoo Chang; Jiin Ahn; Seungho Ryu; Juhee Cho; Eliseo Guallar; Chong Il Sohn
Journal:  Gastric Cancer       Date:  2019-12-18       Impact factor: 7.370

2.  Plasma VEGF and Leptin Values in Patients With Gastric Intestinal Metaplasia and Metabolic Syndrome.

Authors:  George Pappas-Gogos; Kostas Tepelenis; Anna Goussia; Constantinos Tellis; Fotis Fousekis; Georgios K Glantzounis; Konstantinos Vlachos
Journal:  Front Oncol       Date:  2022-05-31       Impact factor: 5.738

3.  Dose-dependent association of proton pump inhibitors use with gastric intestinal metaplasia among Helicobacter pylori-positive patients.

Authors:  Yifat Snir; Haim Leibovitzh; Yaara Leibovici-Weissman; Alex Vilkin; Arnon D Cohen; Tzippy Shochat; Yaron Niv; Iris Dotan; Ilan Feldhamer; Doron Boltin; Zohar Levi
Journal:  United European Gastroenterol J       Date:  2021-03-18       Impact factor: 4.623

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.